Introgen to Present ADVEXIN Phase 3 Study Results at Cancer Clinical Trials and Personalized Medicine Conference
News Jul 21, 2008
Introgen Therapeutics, Inc. has announced that the company will present the results from its recently completed Phase 3 trial of ADVEXIN in recurrent head and neck cancer at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine.
The conference will be held July 20-23, 2008 at the Hyatt Regency Monterey in Monterey, CA.
Introgen’s presentation will review the previously announced findings from the Company’s Phase 3 trial which demonstrated that ADVEXIN successfully achieved its primary and secondary efficacy endpoints in the study’s pre-specified p53 biomarker population.
In addition, Introgen will present supplemental statistical analyses that are included in the Company’s Biologics License Application and Marketing Authorization Application in the U.S. and Europe, respectively.
In the largest study of its kind, researchers at Newcastle University have led national research into the treatment of patients with newly diagnosed myeloma. The results, published by The Lancet Oncology, show an improvement for those who received ongoing therapy with a drug called lenalidomide, compared to those not receiving it.READ MORE